Funding For Risky Biotechs Is Returning

Wall Street is opening its coffers again for risky drug developers.

- BEN GLICKMAN

Many small biotechnology companies have struggled to raise money in recent years. Public markets were all but shut. Initial public offerings slowed to a trickle and follow-on share sales, used by already-public companies to raise more funding, wer